EC approves Refixia from Novo for hemophilia B

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said the European Commission approved an MAA for Refixia nonacog beta pegol (N9-GP, pegylated recombinant human Factor IX, PEG-rFIX) for prophylaxis and on-demand treatment of bleeding, including surgical procedures, in patients ages ≥12 with hemophilia B. Novo plans to launch the product in the first European countries in 4Q17...